February 2014- Volume 10, Issue 2

February 2014

In this Issue

Business & Government Policy

Biousian wins patent for possible best-in-class analgesic

Biousian wins patent for possible best-in-class analgesic

BBI-11008 reportedly equivalent to opioids but without addiction or other common opioid side effects

Jazz Pharmaceuticals is jamming

Jazz Pharmaceuticals is jamming

Acquisitions and sales expansion project big revenue growth for 2014

Emergent Biosolutions to acquire Cangene

Emergent Biosolutions to acquire Cangene

U.S. company seeks to boost role in biodefense market with addition of three products from Canadian company

A CRISPR collaboration

A CRISPR collaboration

Horizon Discovery, Desktop Genetics team up to develop gene-editing platform

Sensible split

Sensible split

AstraZeneca and Bristol-Myers Squibb end diabetes alliance

Preclinical

Going predictive with in-vitro assays

Going predictive with in-vitro assays

Hamner Institutes and Cellular Dynamics collaborate to develop assays using human iPS cell-derived hepatocytes

Building bridges

Building bridges

NIH program gives small business and academia tools for advancing translational science initiatives

Roche, Prothena take aim at Parkinson’s

Roche, Prothena take aim at Parkinson’s

Collaboration could total $600 million if all milestones are met

Research & Development

Thermo sells units to speed up Life acquisition

Thermo sells units to speed up Life acquisition

GE Healthcare will pay $1.06 billion for Thermo Fisher’s cell culture, gene modulation and magnetic beads businesses

Proactive product discovery

Proactive product discovery

Inserm Transfert and GSK sign agreement on immune checkpoint modulators for cancer treatment.

United we stand; divided we fall

United we stand; divided we fall

Global Biological Standards Institute (GBSI) sets unified standards for life-science research

Downsizing has major benefits

Downsizing has major benefits

New University of Queensland technique can shrink and stabilize proteins

Discovery

G8 gathers to confront Alzheimer’s

G8 gathers to confront Alzheimer’s

Global dementia consortium aims to defeat Alzheimer’s disease by 2025 through a concerted effort

In-silico inspiration

In-silico inspiration

Compugen selects five potential cancer targets for ADC therapy from its in-silico discovery program

Evotec and Yale collaborate on cancer therapy

Evotec and Yale collaborate on cancer therapy

Inaugural joint effort will explore novel mechanisms, targets and compounds that have the potential to interfere with DNA repair

Life Technologies releases siRNA data publicly

Life Technologies releases siRNA data publicly

NIH data-sharing collaboration with the company hands over gene-silencing data to help all scientists better understand disease

Receptos transfers GPCR technology to Ono

Receptos transfers GPCR technology to Ono

Proprietary high-res protein crystal structure determination platform enables rational drug design for GPCR target class

Diagnostics

Siemens enters into master agreement with Pfizer

Siemens enters into master agreement with Pfizer

Deal calls for design, development and commercialization of diagnostic tests for a wide range of Pfizer therapeutic products

Saving lives with testing

Saving lives with testing

New test can help detect suicide danger in patients on antidepressants

A CDx for onapristone

A CDx for onapristone

Arno Therapeutics Selects Leica Biosystems to develop companion diagnostic for targeted oncology therapy

Bringing rare diseases to light

Bringing rare diseases to light

Genzyme and NORD establish patient assistance program to help undiagnosed patients with rare diseases

Feature

Show Preview: Something for everyone at Pittcon

Show Preview: Something for everyone at Pittcon

Drug discovery and development professionals may want to give Pittcon a closer look if they haven’t already

Q&A

Seth Lederman: Looking to past medications for the future (Part 1 of 2)

Seth Lederman: Looking to past medications for the future (Part 1 of 2)

To find out a bit more about the philosophy and practice of retooling old drugs for new purposes, DDNews spoke with Dr. Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals

Clinical Trials

Happy news in hep C

Happy news in hep C

AbbVie reports 96-percent sustained virologic response at 12 weeks in Phase 3 trial of 3D regimen

IBD- related anemia therapy delivers ‘robust’ results

IBD- related anemia therapy delivers ‘robust’ results

Shield Therapeutics’ ST10 meets both primary and secondary endpoints in pivotal AEGIS Phase 3 program

Janssen-Pharmacyclics Phase 3 study stopped early

Janssen-Pharmacyclics Phase 3 study stopped early

Progression-free survival and overall survival justify early end to study of Imbruvica vs. ofatumumab

Anti-infective assets

Anti-infective assets

The Medicines Company acquires Rempex, resulting in gain of QIDP drug

Special Reports

A view to biologics

A view to biologics

The pending patent cliff means companies need to take a second look

Editor's Focus

Too much of a therapeutic thing?

Too much of a therapeutic thing?

No matter how good something is, there can always come a point at which there is too much of it. One example of that can be found in the rush to develop cancer therapeutics by so many companies, which may lead to diminishing returns for those companies as well as leave other therapeutic areas to languish.

Commentary

Let’s thank the engineers

Let’s thank the engineers

In December, DDNews columnist Peter Kissinger took some time to celebrate instrumentation and all it has done to facilitate advances in the life sciences, and now he takes the time to shine a spotlight on the engineers who make so much possible

Commentary: Companion diagnostics--Making drug delivery personal

Commentary: Companion diagnostics--Making drug delivery personal

As a patient-centric shift continues to sweep our healthcare system, pharmaceutical companies are increasingly seeing the value of targeting treatments to specific patient populations, making the therapy more personal
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue